The Future of Real-World Evidence in Oncology

Real-world evidence (RWE) has been a crucial element in accelerating research and improving care worldwide, especially during the COVID-19 pandemic. Oncology, however, has led the trend and relied on RWE and real-world data (RWD) since before the pandemic, helping researchers account for the complex underlying factors and social determinates of health (SODH). Ina new AJMC paper, authors Michael Vasconcelles, MD, and Brad Jordan, PhD, explore how oncology has benefited patients and the field in clinical trials and market access.

According to the authors, “We know that patients who receive care in these centers may not be fully representative of the broader population of patients with cancer, which may, in some cases, limit the generalizability of these data. The result may be barriers to enrollment in clinical trials of novel and potentially lifesaving cancer treatments and access to the resulting advanced diagnostics, therapies, or other interventions once they are approved.”

Click here to read the full report.

(Source: AJMC, April 15^th, 2022)